Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM0DLGO)

Drug Name	LY3090106 DM0DLGO
Synonyms	Tibulizumab
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 2/3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sjogren syndrome	DISUBX7H	4A43.20	Phase 2/3	[1]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Rheumatoid arthritis	DISTSB4J	FA20	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04563195) BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (BAFF/IL-17). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT01925157) A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA). U.S. National Institutes of Health.